Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Chronic Disease Prevention and Health Promotion. PCD provides an open exchange of information and knowledge among researchers, practitioners, policy makers, and others who strive to improve the health of the public through chronic disease prevention.
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
News provided by
Share this article
FUJIFILM
CAMBRIDGE, Mass., and MADISON, Wis., May 17, 2021 /PRNewswire/ BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder, focusing on developing cell therapies for patients with ocular diseases, today announced that they have entered into a strategic research and development (R&D) alliance.
Reports Summarize Public Health Findings from RTI International (State-level Health Care Expenditures Associated With Disability) insurancenewsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insurancenewsnet.com Daily Mail and Mail on Sunday newspapers.